



**Supplement Table S1.** Five-year survival and recurrence. Recidive and residual were defined as a recurrence appearing over and under six months after end of treatment, respectively.

		N	%
Five-year survival	Living	569	55,1
	Died of HNSCC	316	30,6
	Died of other cause	148	14,3
Recurrence in five years	No	626	60,6
	Residual	192	18,6
	Recidive	215	20,8



**Supplement Figure S1.** Overall survival (A), disease-specific survival (B) and disease-free survival (C) comparison between p16- and p16+ in HNSCC OPSCC patients excluded.



**Supplement Figure S2.** Overall survival comparison between RT and CRT treatments in p16+ (A) and p16- (B) OPSCC patients.